Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy have developed ...

Small-cell lung cancer (SCLC) is an aggressive form of lung cancer that displays rapid proliferation ... Herein, we review the current treatment paradigm of immunotherapy in SCLC and discuss future ...

With 44,000 new diagnoses each year, non-small cell lung cancer is the second most frequent neoplasm in Italy after breast ...

Cancer a life-threatening disease can spread or metastasise from its original location to other parts of the body The lungs are a frequent site of metastasis An oncologist explains why ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

Molecular profiling and genetic testing have revolutionised lung cancer treatment, says a doctor. They have enabled targeted ...

Terrence Wise’s medical mistreatment at the notorious federal lockup reduced his chance of surviving past five years to about ...

“This data supports our hypothesis of personalized immunotherapy with Bria-OTS™, potentially leading to new and effective ...

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.